Omontys was accepted by the US Food and Drug Administration in March 2012 instead of recombinant versions of the hormone erythropoietin, which indicators the bone marrow to create more red bloodstream cells, for individuals undergoing kidney dialysis. A man made peptide that activates erythropoietin receptors, Omontys offered several advantages over additional erythropoietin-boosting options, including longer-lasting results that reduced the frequency of injections here . Whereas neutralizing antibodies occurred in just just a little over 1 percent of sufferers taking Omontys, it is not really known what caused the allergies that led to the recall.